Navigation Links
Takeda San Francisco, Inc. Appoints Michael Buckley, Ph.D. Vice President of Process Sciences
Date:10/12/2009

SAN FRANCISCO, Oct. 12 /PRNewswire/ -- Takeda San Francisco, Inc. announced today that Michael Buckley, Ph.D., has joined the company as vice president of process sciences. Dr. Buckley will be responsible for directing all aspects of the materials supply to support research and prepare for production of therapeutic antibody candidates at Takeda's antibody IND engine and center of excellence for biologics.

"Mike brings over 20 years of experience in the biopharmaceutical industry and is a great addition to the Takeda San Francisco management team," said Mary Haak-Frendscho, Ph.D., president and chief scientific officer, Takeda San Francisco. "Mike's extensive experience covers all key aspects of antibody drug production, purification, formulation and analytical development. He will play an important role as we expand Takeda's biologics R&D capabilities in order to realize our goals of discovering and advancing superior therapeutics to contribute to the health of individuals."

Dr. Buckley previously has held executive positions with Neugenesis Corporation, Genitope Corporation and Corixa Corporation, leading multi-disciplinary groups in process development, manufacturing and materials management. He also has written multiple IND, BLA and drug master file sections for regulatory submissions. While at Corixa, Dr. Buckley was instrumental in the development of the first centrally manufactured radiopharmaceutical-Iodine-131 antibody (Bexxar(TM)). He holds a Ph.D. in immunology from the UMDNJ Graduate School of Biomedical Sciences, Newark, NJ.

About Takeda San Francisco, Inc.

Takeda San Francisco, Inc. (TSF), established in November 2007 as a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Osaka, Japan, is Takeda's Biologics Center of Excellence and Antibody IND Engine for human antibody therapeutics for the treatment of cancer, inflammation and metabolic diseases. TSF supports T
'/>"/>

SOURCE Takeda San Francisco, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Takeda to Establish Four Sales and Marketing Subsidiaries to Expand Its Operations in Mexico, Turkey and Five Other Countries in Europe
2. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
3. Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
4. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
5. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
6. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
7. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
8. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
9. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
10. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
11. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... 2015  Obsidian HDS, the developer of PharmaShine ( ... the management of data on pharmaceutical and device industry ... includes the 2014 Open Payments General and Research data ... 30. The data disclosed on Open Payments for 2014 ... providers totaling $6.49 billion and is the largest public ...
(Date:7/2/2015)... VANCOUVER , July 2, 2015 /PRNewswire/ - ESSA ... that its common shares have been approved for listing and ... "EPIX". ESSA will begin trading on NASDAQ on ... the TSX Venture Exchange under the symbol "EPI". ... on the NASDAQ, each of the Company,s outstanding special warrants ...
(Date:7/2/2015)... Releases of the genetically engineered ... , , reduced the dengue mosquito population in ... by 95%, well below the modelled threshold for epidemic ... The journal PLOS Neglected Tropical Diseases published today ... mosquitoes. The results showed that in Juazeiro city, northeast ...
Breaking Medicine Technology:New Open Payments (Sunshine Act) Data Now Searchable on PharmaShine 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 3ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 4Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 2Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 3
... The number of Americans who are obese will increase ... less than twenty years, a recent study says. 1 ... specifically designed for individuals suffering from obesity and associated diseases ... of the centers and professionals we work with, is to ...
... 10, 2011 Cantel Medical Corp. (NYSE: CMN ... fiscal year ended July 31, 2011 on Thursday, October 13 ... discuss the results at 11:00 AM ET.  Participating in the ... President and CEO; Seth R. Segel, Executive Vice President; and ...
Cached Medicine Technology:1-800-GET-THIN Agrees With Report Calling for Better Eating Habits 2Cantel Medical Corp. to Hold Conference Call to Discuss Fourth Quarter and Fiscal 2011 Results 2
(Date:7/3/2015)... (PRWEB) , ... July 03, 2015 , ... ... for enrollment on July 2nd creating a buzz of media attention. In an ... published online by HonestyFirstReviews.com's Tiffany Hendricks. , "These days many people are feeling ...
(Date:7/3/2015)... , ... July 03, 2015 , ... Scientists at several ... to mesothelioma with even minimal asbestos exposure. Click here to read the complete ... University of Hawaii Cancer Center, Cedars Sinai Medical Center, and New York University exposed ...
(Date:7/3/2015)... ... July 03, 2015 , ... B. E. Smith, the ... to lead a national chief nursing officer recruitment for Jane Phillips ... the healthcare industry, B. E. Smith has recently placed more than 1,000 healthcare ...
(Date:7/3/2015)... ... July 03, 2015 , ... Talcum powder attorneys representing ... their existing Talcum Powder Cancer Lawsuit Center website. Just as the previous version did, ... news , offering timely lawsuit updates and ovarian cancer warning information. The site is ...
(Date:7/3/2015)... ... ... " Selfie on a Stick ” was featured on NewsWatch as part of its ... Amanda Forstrom, a technology expert and special reporter for NewsWatch, conducted the review and ... every smartphone has an incredibly powerful camera built into it. And when someone is ...
Breaking Medicine News(10 mins):Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 2Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 3Health News:Study Finds Small Amounts of Asbestos May Trigger Mesothelioma in People with Genetic Mutation, According to Surviving Mesothelioma 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3Health News:Learn How to Take Selfies like Kendall Jenner 2
... , TUESDAY, Feb. 21 (HealthDay News) -- Watching a lot ... teens will start drinking, and these teens are more likely ... The researchers said their findings suggest that U.S. movie ... they have for tobacco. The study included more than ...
... can save smokers, lives, and there is a scientific ... Brad Rodu, D.D.S., professor of medicine at the University ... Chair in Tobacco Harm Reduction at UofL,s James Graham ... the American Association for the Advancement of Science Feb. ...
... 17 (HealthDay News) -- Knees with osteoarthritis are in a ... researchers say. The discovery was a surprise, said study ... at Duke University Medical Center in Durham, N.C. The ... know about and the main treatment strategy probably would need ...
... HealthDay Reporter , FRIDAY, Feb. 17 (HealthDay News) -- Decades-old assumptions about ... put 100 out of reach for many seniors, a new study finds. ... as you age. A team of researchers now believe that ... instead of flattening out a bit. The findings could lead to ...
... -- Complication rates for women older than 50 who ... of younger women, according to a new study. ... women are at higher risk for pregnancy complications such ... and placenta abnormalities, the Columbia University Medical Center researchers ...
... Education (AGHE) the educational branch of The Gerontological ... Meeting and Educational Leadership Conference from February 23 to ... Arlington, VA. Media representatives are invited to attend free ... professionals in the field of aging to present their ...
Cached Medicine News:Health News:Booze in Movies May Fuel Teenage Drinking 2Health News:UofL research shows substituting with smokeless tobacco saves lives 2Health News:Arthritic Hip May Be Tougher to Treat Than Knee 2Health News:Living to 100 May Be Tougher Than You Think 2Health News:Age Doesn't Raise Complication Risk for Pregnancies With Donor Eggs 2Health News:Meeting to outline effective education about aging as America's senior population grows 2
All oral and nasal airways are manufactured with smooth, rounded edges for increased patient comfort and safety., ,Portex® offers a broad selection of airways for a variety of clinical applicati...
... latex. Available in even sizes 20-36F. ... maximizing patient comfort., ,The Latex-Free ... maximize patient comfort while offering the ... is economically priced allowing you to ...
Soft red rubber. Adjustable flange. Pediatric sizes available....
Soft Non-Latex, Adjustable Flange Nasopharyngeal Airway. Pediatric sizes available. Non-Latex Mediprene material with soft elastic finish. Adjustable flange for a better fit and increased patient com...
Medicine Products: